Phase 2
N=21
Cabozantinib and Pembrolizumab in Metastatic Pancreas
Pancreatic Cancer
Bottom Line
View on ClinicalTrials.gov: NCT05052723 ↗Enrolled (actual)
21
Serious AEs
61.9%
Results posted
Nov 2025
Primary outcome: Primary: Progression-free Survival — 2 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Cabozantinib (Drug); Pembrolizumab (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Joseph Kim
- Primary completion
- Nov 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Progression-free Survival |
2 | — |
| SECONDARY Number of Participants With Response to Therapy |
1 | — |
| SECONDARY Number of Participants With Complete Response |
— | — |
| SECONDARY Number of Participants With Partial Response |
1 | — |
| SECONDARY Overall Participant Survival Rate |
2 | — |
Summary
This study aims to evaluate cabozantinib and pembrolizumab for the treatment of metastatic pancreatic adenocarcinoma.
Eligibility Criteria
Inclusion Criteria
- Diagnosis of pancreatic ductal adenocarcinoma
- Evidence of progression or intolerance to previous standard of care pancreatic cancer systemic or locoregional therapies
- Patients must have adequate organ function
Exclusion Criteria
- Chemotherapy or other locoregional anti-tumoral therapies performed within 28 days of study treatment initiation
- Received palliative radiation therapy within 2 weeks or any other radiation therapy within 4 weeks of start of study intervention
- Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to allocation
- Has a diagnosis of immunodeficiency (autoimmune disease) or is receiving chronic systemic steroid therapy
- Clinically significant cardiovascular disease
- Uncontrolled hypertension
- Inability to swallow tablets
Data sourced from ClinicalTrials.gov (NCT05052723). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.